Congestive Heart Failure (CHF) and Cardiomyopathy

Chronic obstructive pulmonary disease (COPD) is one of the most common lung diseases. It makes it difficult to breathe. There are two main forms of COPD: chronic bronchitis, which involves a long-term cough with mucus, and emphysema, which involves the destruction of the lungs over time. Most people with COPD have a combination of both conditions. Smoking is the leading cause of COPD. Standard treatment includes the use of bronchodilator inhalers, steroids, and supplemental oxygen.

Chronic Obstructive Pulmonary Disease (COPD) and CSCTC

Cell therapy potentially offers an important solution for CHF and cardiomyopathy. During cardiac ischemia, millions of myocytes are lost resulting in loss of contractile function. One of the great goals of regenerative medicine is to engineer methods of replacing these cells.  Research studies show that adipose-derived mesenchymal stem cells are playing an important role in this regeneration. There is also a growing body of data supporting the use of engineered biologics such as selected cell populations, organic scaffolds, and modified (differentiated or de-differentiated) stem cells to regenerate damaged myocardium. It is unknown whether the cost of engineered biologics over harvested stem cells is justified until long-term studies are available. The results of clinical trials of the use of adult mesenchymal stem cells to treat cardiac disease have demonstrated safety and most have shown positive clinical results. Mesenchymal stem cells have been deployed intravenously, injected the myocardium, and placed in the coronary arteries and it is still unclear if one delivery method is clearly superior to another. It is also unclear which source of mesenchymal cells is optimal for cardiac regeneration but adipose derived cells appear to be highly effective in this area.

Congestive Heart Failure and CSCTC Deployment Protocol

Research has been ongoing around the world that exploits the anti-inflammatory and regenerative properties of adult stem cells to mitigate heart failure. Chicago Stem Cell Treatment Center is investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on CHF. We use a protocol designed by our interventional cardiologist that includes intravenous deployment. The CSCTC deployment protocol is performed under local anesthesia and is all done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately 3 hours.

Schedule your Consultation with Dr. Ritacca Today

Do you have additional questions on how stem cells work and how they relate to your condition?  Contact us today to schedule a consultation with Dr. Ritacca, Founder of the Chicago Stem Cell Treatment Center.  To get the process started, simply fill out our short stem cell candidate form. Once we receive the application, a stem cell coordinator will call you to schedule your phone or in-person consultation with Dr. Ritacca. We look forward to educating you on the latest research for stem cell therapy.